Objective: Combined paclitaxel and carboplatin is a standard regimen for inoperable nonsmall cell lung cancer (NSCLC). Although an every-3-week schedule is common, weekly paclitaxel is clinically effective for various cancers. A Phase I clinical trial was conducted to determine maximum-tolerated doses (MTDs) for weekly combined paclitaxel and carboplatin, and to evaluate anti-tumor response, toxicity and pharmacokinetics of paclitaxel in patients with inoperable NSCLC. Methods: Twenty patients with inoperable NSCLC received weekly carboplatin at area under the curve (AUC) ¼ 2 mg/ml min and paclitaxel. Paclitaxel was escalated if MTD was not reached. Three patients each were entered at levels 1 and 2 (level 1, paclitaxel 50 mg/m 2 and carboplatin AUC ¼ 2 mg/ml min; level 2, 60/2), six at level 3 (70/2), five at level 4 (80/2) and three at level 5 (90/2). Results: One patient had grade 4 (G4) neutropenia at level 2, one had G3 hepatic toxicity at level 3 and one had G3 cardiac toxicity at level 4. MTD was not reached for all dose levels. Response rate (RR) was 35% (7/20) and median survival was 11.1 months. Severe neutropenia (G3 and G4) was seen in seven patients associated with greater AUC, peak concentration (C max ) and the duration of plasma concentration .50 ng/ml of paclitaxel. Conclusions: Weekly combined paclitaxel (up to 90 mg/m 2 ) and carboplatin (AUC ¼ 2 mg/ ml min) was well tolerated. A higher dose intensity of paclitaxel can be given, and RR and survival are not less than the every-3-week protocol. The weekly regimen is an alternative for untreated inoperable NSCLC patients.
INTRODUCTION
Lung cancer is the leading cause of cancer deaths in many countries, including Japan. Non-small cell lung cancer (NSCLC) comprises $80% of all lung cancer cases. Nearly half of all patients with NSCLC are not candidates for curative surgery at the time of diagnosis (1) . The prognosis for these inoperable NSCLC patients is still poor, even though new chemotherapy regimens are available.
Paclitaxel þ carboplatin is one of the standard regimens for NSCLC. Paclitaxel, the first of the taxane anti-microtubule agents, showed overall response rates (RRs) of .30% in a Phase II study of NSCLC in Japan (2, 3) . The typical doses for the two drugs during a 3-week protocol are 200 mg/m 2 for paclitaxel and area under the curve (AUC) ¼ 6 mg/ml min for carboplatin in Japan (4) . However, the best administration method for paclitaxel is still under investigation.
In vitro experiments using lung, breast and ovarian cancer cell lines showed that prolonging the exposure to paclitaxel above a threshold concentration was more effective than a short-term exposure to a higher drug concentration (5, 6) . Thus, weekly administration of paclitaxel is worth investigating for possibly better effects and reduced toxicity. The clinical utility of weekly paclitaxel administration has been demonstrated for various cancers (7 -9) . Weekly carboplatin treatment is also effective in combination chemotherapy (10) . Further, weekly administration of both paclitaxel and carboplatin is being investigated in NSCLC, ovarian cancers and other solid tumors (11, 12) . One purpose for weekly administrations of paclitaxel is to maintain the time of antitumor plasma concentrations as long as possible without increasing toxicity.
Hematological toxicity for paclitaxel was reported to be related to the duration of the time that the plasma paclitaxel concentration was !50 -100 nM (13, 14) . However, there are no reports regarding hematological toxicity and plasma paclitaxel concentrations for the weekly administration of a combination treatment with carboplatin. In this study, we wanted to elucidate the relationship between the duration of plasma paclitaxel concentration .50 nM and hematological toxicity during weekly administrations of paclitaxel combined with carboplatin.
Therefore, we conducted a Phase I study to determine the maximum-tolerated dose (MTD) and recommended dose for weekly combinations of paclitaxel and carboplatin, and to evaluate the anti-tumor response, toxicity and the pharmacokinetics of paclitaxel in patients with inoperable NSCLC.
PATIENTS AND METHODS

STUDY DESIGN
This trial was a single institution, prospective, single-arm Phase I study. This study was performed at Yokohama Municipal Citizen's Hospital. The protocol was approved by the institutional review board of Yokohama Municipal Citizen's Hospital and Japan Clinical Oncology Group (JCOG). Each patient gave written informed consent before enrollment.
PATIENT SELECTION
Patients eligibility requirements for entering into this study included the following criteria: histologically or cytologically confirmed NSCLC; measurable or assessable disease at stages IV and IIIB without curative radiotherapy; age 75 years or younger; no prior chemotherapy or radiotherapy; and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 -1. Additional criteria were: expected survival !3 months; adequate organ functions; leukocyte count !4000/mm 3 ; neutrophil count !2000/mm 3 ; platelet count !100 000/mm 3 ; hemoglobin level !9.5 g/dl; total bilirubin within upper limit of normal range; AST/ALT 2 Â upper limit of normal range; creatinine 1.5 Â upper limit of normal range; 24 h creatinine clearance (CCR) !30 ml/min; and PaO 2 !70 mmHg. Exclusion criteria included other active malignancy, pleural effusion or pericardial effusion requiring medical treatment, symptomatic brain metastases, superior vena cava syndrome requiring radiotherapy, history of myocardial infarction within 3 months, serious medical illness, history of severe anaphylaxis, history of anaphylaxis to castor oil, pregnancy or lactation.
Staging procedures included chest x-ray, computed tomography (CT) scan of the chest, CT scan of the brain, CT scan or ultrasound of the abdomen and isotope bone scanning.
TREATMENT PLAN
The trial was designed as a dose-escalation study of paclitaxel and carboplatin used in weekly combination therapy. The dose of carboplatin was fixed to target weekly AUC ¼ 2 mg/ml min. The starting weekly dose of paclitaxel was 50 mg/m 2 given over 1 h. If treatment was well tolerated, then successive dose levels were increased at intervals of 10 mg/m 2 in groups of three patients to 60, 70, 80 and 90 mg/m 2 . The initial dose level was determined to be nearly equivalent to, but not to exceed, the typical dosage of a 3-week regimen of carboplatin (AUC ¼ 6 mg/ml min) þ paclitaxel (200 mg/m 2 ). Dose-limiting toxicity (DLT) was defined as: (i) grade 4 (G4) (!4 days) leukopenia; (ii) G4 (!7 days) neutropenia; (iii) fever (!388C) with G4 leukopenia or neutropenia; (iv) thrombocytopenia 25 000/mm 3 or requiring platelet transfusion; (v) any G3/4 nonhematological toxicities, except nausea, vomiting or hair loss; and (vi) a delay for the following cycle within 2 weeks. The National Cancer Institute (NCI) common toxicity scale was used to grade adverse events (15) . If no patient experienced DLT, then subsequent patients entered the study at the next greater dose level. If one or two of the three patients experienced DLT, then subsequent patients entered at the same level, for a total of four to six patients. If more than three of the four to six patients had DLT at a specific dose level, this was defined as the MTD. If less than one of five or less than two of six patients had DLT, the next level will be entered. The recommended dose would be decided 1 level under the MTD, with special consideration for safety and efficacy. The MTD was determined according to the results following the first three administrations of the drugs. In the case of early discontinuation with three administrations, the MTD was determined at the time of discontinuation of the treatment.
CHEMOTHERAPY
Paclitaxel and carboplatin were administered on day 1 by intravenous (iv) infusion. Chemotherapy was repeated weekly for at least six cycles unless there was no progression of the disease. Patients who received at least six cycles were considered to have completed treatment. Treatment after protocol completion or disease progression was up to the responsible doctor. All patients received the following pre-medications 30 min before the paclitaxel infusion: dexamethasone 20 mg iv; diphenhydramine 50 mg po; and ranitidine 50 mg iv. Anti-emetics, such as granisetron, were also administered as pre-medications. Paclitaxel was administered over 1 h. Thirty minutes after the paclitaxel infusion, carboplatin at AUC ¼ 2 mg/ml min according to the Calvert
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Weekly paclitaxel and CBDCA for inoperable NSCLC formula (16) was delivered as an iv bolus infusion over 1 h. The carboplatin dose was based on the actual glomerular filtration rate (GFR) calculated by the measurement of
. Subsequent courses of chemotherapy were initiated when the following criteria were met: leukocyte count !2000/mm 3 , neutrophil count !1000/ mm 3 , platelet count !50 000/mm 3 within 24 h of the day of treatment; nephrotoxicities G2; hepatic toxicities G1; fever , 388C or PS 2; neurological toxicities G1; and stomatitis G1. If the above criteria were not satisfied by the first day of the next course, treatment was withheld until recovery. If more than 3 weeks passed from day 1 of the last course, the patient was taken out of the study. Treatment was discontinued if the disease progressed, the patient withdrew or experienced septic shock, if there was G3 neurological toxicity or G4 non-hematological toxicity, if there was a treatment delay of more than 3 weeks, repeated toxicity after dose modification, or by a decision of the clinician. Dose modifications were made after the first administration based on toxicity. Patients had their paclitaxel dose reduced by 25% if they experienced G4 leukopenia !4 days, G4 neutropenia !7 days, fever (!388C) with G4 leukopenia or neutropenia, G3 hepatic toxicity, G3 neurological toxicity or G3 stomatitis. Patients had their carboplatin dose reduced by 25% if they experience fever (!388C) with G4 leukopenia or neutropenia, thrombocytopenia 25 000/mm 3 or requiring platelet transfusion, G3 hepatic toxicity or G3 stomatitis. In case of nephrotoxicity grade !2, CCR would be measured and the carboplatin dose adjusted according to this result.
EVALUATION
Toxicities were evaluated according to the NCI common toxicity scale (15) . Tumor responses were evaluated according to World Health Organization criteria (17) . Response was determined at the end of the treatment if the protocol was completed. If the treatment was stopped earlier, response was determined at the time of protocol discontinuation. Overall survival (OS) was determined from the time of registration to death or the last follow-up evaluation.
STATISTICS
This trial was a single institution, prospective, single-arm Phase I study. The primary endpoint was toxicity, and the secondary endpoints were anti-tumor effect (RR and survival) and pharmacokinetics of paclitaxel. Analysis of the trial was based on the intention-to-treat principle. OS were calculated using the method of Kaplan and Meier.
PHARMACOKINETICS
For the pharmacokinetic study of paclitaxel, each patient gave written informed consent for this study separately from the treatment protocol. During the first course of the treatment, a 2 ml blood sample was withdrawn from patients at 0, 0.5, 1.5, 3, 6, 10, 24, 48, 72 and 96 h after paclitaxel treatment (total of 20 ml). The time for blood sampling was according to previous reports during the first 10 h (18, 19) , and after this, they were determined every 24 h. Heparin was added to the blood and stored at 48C. Plasma was separated by centrifugation and stored at -208C. Plasma paclitaxel concentrations were measured using an HPLC method. Table 1 ). The median age was 67 years, 85% were male, 70% had adenocarcinoma and 70% were stage IV.
RESULTS
PATIENT CHARACTERISTICS
Between March 2000 and November 2003, 20 patients were registered and all received chemotherapy (
TOXICITIES OF THERAPY
One of 3 patients experienced G4 neutropenia at level 2, but none of the other 19 patients had G4 hematological toxicities ( Table 2 ). None had febrile neutropenia. Seven of 20 patients (35%) had G3/4 neutropenia, and 1 of 20 patients (5%) had G3/4 thrombocytopenia. With regard to non-hematological Jpn J Clin Oncol 2009;39(9) 571 toxicities, one of six patients had G3 hepatic toxicity at level 3, and one of five patients had G3 cardiac toxicity (angina) at level 4 (Table 3) . Only these two cases had DLT. There were no treatment-related deaths. One case (5%) had an allergic reaction, but none had G3/4 neurological toxicity. MTD was not reached for all dose levels (Table 4) . A weekly combination of paclitaxel and carboplatin was well tolerated, and a higher dose intensity of paclitaxel could be given to patients compared with the standard every-3-week regimen of paclitaxel (Table 5) .
THERAPEUTIC RESPONSE AND OS
The RR was 35% (7/20; Table 4 ), and the median survival time (MST) was 337 days (11.1 months).
PHARMACOKINETICS
The pharmacokinetics of paclitaxel was examined in all 20 patients (Tables 6 and 7 ). The AUC, peak plasma concentration (C max ) and the duration of plasma concentration .50 ng/ml (duration of C . 50 ng/ml) were increased in proportion to the increase in paclitaxel dose level (Table 6) .
Severe neutropenia (grades 3 and 4) was observed in seven patients and was associated with a greater AUC, C max and the duration of C . 50 ng/ml (Table 7) . Pharmacological responses had the tendency of association with increased pharmacokinetic parameters of paclitaxel (Fig. 1) .
DISCUSSION
This is a Phase I clinical trial for a weekly combination of paclitaxel and carboplatin that was conducted to determine the MTD and to evaluate toxicity, anti-tumor response and the pharmacokinetics in patients with inoperable NSCLC. In this study, a weekly combination of paclitaxel and carboplatin was well tolerated, and a higher dose intensity of paclitaxel could be given to patients compared with a standard, every-3-week regimen of paclitaxel.
The combination of paclitaxel (225 mg/m 2 ) and carboplatin (AUC ¼ 6 mg/ml min) administered every 3 weeks is the most commonly used chemotherapy regimen in the USA for the treatment of advanced and metastatic NSCLC. The RR with this regimen ranges from 17% to 25%, with MST ranging from 8 to 10 months (20 -23) . In this study, the RR was 35% and the MST was 337 days (11.1 months). In a randomized Phase II trial comparing three different regimens of Table 2 . Hematological toxicity 
Number of course (median) 6 9 5.5 7 6
Withdrawal by toxicity Table 3 . Non-hematological toxicity 
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Weekly paclitaxel and CBDCA for inoperable NSCLC weekly paclitaxel and carboplatin, Belani et al. (24) showed that the most favorable regimen was paclitaxel (100 mg/m 2 ) weekly for 3 of 4 weeks with carboplatin (AUC ¼ 6 mg/ ml min) on day 1 every 4 weeks. This showed an RR of 32% and an MST of 49 weeks, comparable to our results. They also showed 5% with G3/4 neuropathy, 2% with G3/4 febrile neutropenia and 22% with G3/4 neutropenia for that treatment, compared with 0%, 0% and 35% in our study. Even though the sample size was smaller in our study, the toxicities appear to be comparable and tolerable.
In spite of the initial promising report of a weekly regimen (24), a Phase III trial that compared a weekly regimen with a standard every 3 weeks with carboplatin and paclitaxel failed to show a survival or response benefit for the weekly approach (25) . In contrast, Socinski et al. (26) reported that RR and survival outcomes were similar in a Phase II trial comparing every-3-week carboplatin and paclitaxel with every-3-week carboplatin and weekly paclitaxel. However, the toxicity profiles were different between the two regimens, suggesting that the weekly regimen is a feasible and acceptable alternative for certain patients such as the elderly and/or poor PS patients. In many trials with weekly paclitaxel, carboplatin is often combined with monthly or tri-/bi-weekly administration. Weekly administrations of both drugs were done in two Phase II trials and one Phase III trial (11, 24, 27) . Although the original Belani et al.'s (24) trial showed that monthly carboplatin was the most favorable therapeutic index compared with other weekly carboplatin regimens, a recent Phase III trial showed comparable results with both weekly paclitaxel and carboplatin compared with a standard 3-week regimen (27) . Schuette et al. (27) used weekly paclitaxel (100 mg/m 2 ) and carboplatin (AUC ¼ 2 mg/ml min). This showed an RR of 38% and an MST of 8.9 months, compared with an RR of 33% and an MST of 9.5 months for every-3-week paclitaxel (200 mg/ m 2 ) and carboplatin (AUC ¼ 6 mg/ml min), and less frequent !G3 neuropathy in the weekly regimen (4.4% vs. 9.1%). A small Phase II study with weekly administration of both paclitaxel and carboplatin (100 mg/m 2 for paclitaxel and AUC ¼ 2 mg/ml min for carboplatin; weekly for 3 of 4 weeks; n ¼ 30) reported a 43.5% RR and 10.8 months MST (11) . Regarding toxicities, only 1 of 30 patients (4%) suffered from G3 neurotoxicity. Our results also suggest that the toxicities were acceptable. In fact, a subanalysis of the Phase II and III studies showed comparable efficacy and a favorable tolerability profile for a weekly regimen in elderly patients (28, 29) . Several Phase II results also showed reasonable activity and acceptable toxicities in the elderly and/or unfit NSCLC patients (12, 30, 31) . Along with these results, our study suggests the feasibility of weekly carboplatin/ paclitaxel trials for the treatment of NSCLC patients with modest activity, and that this regimen may be especially suitable for elderly and/or unfit patients.
In Japan, results from several Phase I and I/II studies were reported (32 -34) . In a Phase I trial of advanced NSCLC (32), a recommended dose level of paclitaxel was 70 mg/m 2 on days 1, 8 and 15 in combination with carboplatin (AUC ¼ 6 mg/ml min) on day 1 of a 4-week cycle. In a Phase I study with the same treatment schedule (carboplatin: AUC ¼ 6 mg/ml min with weekly paclitaxel in a 4-week cycle), Kikuchi et al. (34) reported a recommended dose level of paclitaxel of 100 mg/m 2 . Although carboplatin was delivered weekly in our trial, the recommended dose of paclitaxel was .90 mg/m 2 , comparable to the report by Kikuchi et al. (34) . This relatively higher MTD dose in our trial and another Phase I trial (34) compared with that of Hirabayashi et al. (33) may be due to differences in background patient PS (0 -1 vs. 1 -2). In Japan, the usual doses in a 3-week protocol are 200 mg/m 2 for paclitaxel and AUC ¼ 6 mg/ml min for carboplatin (4) . In the Phase III study (4), the RR was 32% and the MST was 12.3 months. Although we cannot draw any definitive conclusions from the comparison between the Phase III trial and our Phase I trial, the RR was comparable and the higher dose of paclitaxel delivery can be achieved by our weekly paclitaxel schedule with an MTD of !90 mg/m 2 . We stopped our dose of paclitaxel at 90 mg/m 2 because this dose is thought to be reasonably comparable to the dose of a regular 3-week regimen (200 -225 mg/m 2 ). Although we could not reach an MTD, for comparisons with other Values are given as mean + SD. Values are given as mean + SD.
Jpn J Clin Oncol 2009;39(9) 573 weekly regimens, paclitaxel with 90 mg/m 2 every week is a reasonably high dose. We may try increasing dosage, but based upon feasibility and the modest activity, the dose levels used here will be suitable for regular practical settings.
The severity of neutropenia in this weekly regimen with paclitaxel and carboplatin was consistent with that observed in patients treated with every-3-week schedules. Belani et al. (13) examined the pharmacokinetics of a combination treatment with paclitaxel and carboplatin (every 3 weeks) in a Phase I trial with metastatic NSCLC. They showed a pharmacodynamic relationship between the duration of the time that plasma paclitaxel concentration was at or above 0.05 mM and relative neutropenia, which is consistent with our study with weekly settings. They also showed that patients who had received carboplatin in combination with paclitaxel experienced less thrombocytopenia than would be expected from carboplatin alone. We did not thoroughly examine this issue, but only 1 of 20 patients (5%) had G3 thrombocytopenia, and none had G4 thrombocytopenia in this trial. It may also be possible in the weekly combination scenario that thrombocytopenia will be limited, although this issue may require further evaluation.
In conclusion, although the every-3-week protocol of paclitaxel and carboplatin is considered to be the standard treatment, the weekly regimen can be an alternative for untreated, inoperable NSCLC patients. A Phase II study is warranted with this treatment protocol, i.e. recommended dose of weekly paclitaxel (90 mg/m 2 ) and carboplatin (AUC ¼ 2 mg/ml min). 
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